ArticleBMJ open respiratory research2020
Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry.
Article in BMJ open respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Impact of time to diagnosis in patients with progressive fibrotic ILD: a systematic review.BMJ open respiratory research · 2026Pooled it
- Interstitial lung abnormalities in a large clinical lung cancer screening cohort: association with mortality and ILD diagnosis.Respiratory research · 2023Trial
- Article
- Diagnosis of early idiopathic pulmonary fibrosis: current status and future perspective.Respiratory research · 2025Review
- Idiopathic pulmonary fibrosis in the UK: findings from the British Thoracic Society UK Idiopathic Pulmonary Fibrosis Registry.BMJ open respiratory research · 2025Observational
- Bifurcation in the healing or fibrotic response in a network model of fibrosis: role of the initial injury structure.Frontiers in network physiology · 2025Article
- Traditional Herbal Plants and their Phytoconstituents Based Remedies for Respiratory Diseases: A Review.The open respiratory medicine journal · 2025Review
- A novel Non-rodent animal model of hydrochloric acid-induced acute and chronic lung injury.Respiratory research · 2024Article
- Multidisciplinary Approach to the Diagnosis of Idiopathic Interstitial Pneumonias: Focus on the Pathologist's Key Role.International journal of molecular sciences · 2024Review
- Circulating biomarker analyses in a longitudinal cohort of patients with IPF.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Pulmonary vessel volume in idiopathic pulmonary fibrosis compared with healthy controls aged > 50 years.Scientific reports · 2023Article
- National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care.BMJ open respiratory research · 2022Article
- Potential interstitial lung abnormalities on chest X-rays prior to symptoms of idiopathic pulmonary fibrosis.BMC pulmonary medicine · 2022Article
- Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates.BMJ open respiratory research · 2022Observational
- Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study.Respiratory research · 2022Article
- Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden.Respirology (Carlton, Vic.) · 2022Article
- Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic.Pharmaceuticals (Basel, Switzerland) · 2021Review
- A New Piece to Help Solve the Interstitial Lung Disease Diagnostic Puzzle.American journal of respiratory and critical care medicine · 2021Article
- Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis: A Multinational European Survey.Frontiers in medicine · 2021Article
- Nicotine Changes Airway Epithelial Phenotype and May Increase the SARS-COV-2 Infection Severity.Molecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a progressive disease with high mortality. Patient characteristics associated with diagnostic delays are not well described.
methodsSubjects who had not been diagnosed with IPF prior to referral and received a new diagnosis of IPF at an enrolling centre for the IPF-PRO (
resultsAmong 347 patients with a symptom onset date, 49% were diagnosed with IPF >1 year after symptom onset. These patients were slightly younger and had more cardiac comorbidities than patients diagnosed ≤1 year after symptom onset. Among 454 patients with a date for imaging evidence of fibrosis, 78% were diagnosed with IPF ≤1 year later. A greater proportion of patients with >1 year versus ≤1 year from imaging evidence of fibrosis to diagnosis had cardiac comorbidities and gastro-oesophageal reflux. There was no significant difference in time to death or lung transplant between groups by time to diagnosis.
conclusionsThe time from symptom onset to diagnosis remains over 1 year in approximately half of the patients with IPF, but once imaging evidence is obtained, most of the patients are diagnosed within a year. Cardiac conditions and gastro-oesophageal disorders were more commonly reported in patients with a longer time to diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.